13F Holdings
中文EN

COYA Coya Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1835022 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.6%
TTM net income YoY-63.7%
TTM EPS YoY-25.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-675.3%
Net margin-643.5%
FCF margin—
EBITDA margin-675.0%

Returns

ROE-99.2%
ROA-84.6%
ROIC (approx.)—
Asset turnover0.13x

Leverage & solvency

Liabilities / assets14.6%
Debt / equity0.00x
Current ratio7.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-23.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$7.95M$3.55M$6.00M$0—
R&D expense$16.73M$11.87M$5.50M$4.41M$2.54M
SG&A expense$11.45M$8.89M$7.83M$4.85M$2.31M
Operating income-$22.56M-$17.25M-$7.90M-$9.81M-$4.87M
Pretax income-$21.22M-$15.60M-$7.26M-$12.24M—
Income tax$3,089-$720,287$723,852$0—
Net income-$21.23M-$14.88M-$7.99M-$12.24M-$4.89M
EBITDA-$22.53M-$17.22M-$7.88M-$9.78M-$4.85M
EPS (basic)-1.27-0.98-0.79-4.73-1.89
EPS (diluted)-1.27-0.98-0.79-4.73-1.89
Weighted avg. shares (diluted)16.73M15.24M10.16M2.59M2.59M
Balance sheet
Cash & equivalents$46.82M$38.34M$32.63M$5.93M$4.34M
Current assets$49.94M$44.31M$41.20M$7.18M$4.58M
PP&E, net$11,227$38,588$65,949$93,310$120,671
Total assets$49.95M$44.35M$41.26M$8.40M$4.79M
Current liabilities$5.87M$3.82M$5.05M$3.82M$1.15M
Total liabilities$6.92M$4.77M$5.63M$16.79M$1.15M
Shareholders' equity$43.03M$39.58M$35.64M-$8.39M$3.64M
Shares outstanding20.93M16.71M14.41M2.59M2.59M
Cash flow statement
Operating cash flow-$10.74M-$10.29M-$11.19M-$7.24M-$3.90M
Investing cash flow-$1.16M-$25,000-$543,186-$525,000-$136,804
Financing cash flow$20.39M$16.03M$38.43M$9.36M-$340,584
Depreciation & amortization$27,361$27,361$27,361$27,361$16,133
Stock-based compensation$4.29M$2.66M$872,248$207,346$233,222

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.